EBS vs. INVA, OPK, IRWD, LXRX, VNDA, XOMA, AGEN, CDXS, ACHV, and RIGL
Should you be buying Emergent BioSolutions stock or one of its competitors? The main competitors of Emergent BioSolutions include Innoviva (INVA), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Lexicon Pharmaceuticals (LXRX), Vanda Pharmaceuticals (VNDA), XOMA (XOMA), Agenus (AGEN), Codexis (CDXS), Achieve Life Sciences (ACHV), and Rigel Pharmaceuticals (RIGL). These companies are all part of the "biotechnology" industry.
Innoviva (NASDAQ:INVA) and Emergent BioSolutions (NYSE:EBS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, community ranking, analyst recommendations, institutional ownership, media sentiment, risk and valuation.
Emergent BioSolutions has a consensus price target of $5.00, suggesting a potential upside of 2.88%. Given Innoviva's higher probable upside, analysts clearly believe Emergent BioSolutions is more favorable than Innoviva.
Emergent BioSolutions received 117 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 66.45% of users gave Emergent BioSolutions an outperform vote while only 57.28% of users gave Innoviva an outperform vote.
In the previous week, Innoviva had 4 more articles in the media than Emergent BioSolutions. MarketBeat recorded 5 mentions for Innoviva and 1 mentions for Emergent BioSolutions. Emergent BioSolutions' average media sentiment score of 1.74 beat Innoviva's score of 0.49 indicating that Innoviva is being referred to more favorably in the media.
99.1% of Innoviva shares are owned by institutional investors. Comparatively, 78.4% of Emergent BioSolutions shares are owned by institutional investors. 1.4% of Innoviva shares are owned by insiders. Comparatively, 1.2% of Emergent BioSolutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Innoviva has higher earnings, but lower revenue than Emergent BioSolutions. Emergent BioSolutions is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
Innoviva has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500.
Innoviva has a net margin of 58.21% compared to Innoviva's net margin of -47.68%. Emergent BioSolutions' return on equity of 28.94% beat Innoviva's return on equity.
Summary
Innoviva beats Emergent BioSolutions on 11 of the 17 factors compared between the two stocks.
Get Emergent BioSolutions News Delivered to You Automatically
Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Emergent BioSolutions Competitors List
Related Companies and Tools
